The clinical pharmacokinetics of the new antiepileptic drugs

Epilepsia

Volumn 40, Issue SUPPL. 9, 1999, Pages

  Perucca, Emilio ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Antiepileptics; Drug interactions; Pharmacokinetics

Indexed keywords

ANTACID AGENT; ANTICONVULSIVE AGENT; BARBITURIC ACID DERIVATIVE; CARBAMAZEPINE; CIMETIDINE; DEXTROPROPOXYPHENE; DIGOXIN; ERYTHROMYCIN; ETHINYLESTRADIOL; FELBAMATE; GABAPENTIN; LAMOTRIGINE; MESUXIMIDE; NAPROXEN; NORMESUXIMIDE; ORAL CONTRACEPTIVE AGENT; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; SALICYLIC ACID DERIVATIVE; THEOPHYLLINE; TIAGABINE; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID; VERAPAMIL; VIGABATRIN; VILOXAZINE; WARFARIN; ZONISAMIDE;

AGE; ANTICONVULSANT THERAPY; COMORBIDITY; CONFERENCE PAPER; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COMPETITION; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; EPILEPSY; HUMAN; ORAL DRUG ADMINISTRATION; PREGNANCY; PRIORITY JOURNAL;

EID: 0032779380     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1157.1999.tb02088.x     Document Type: Conference Paper

References (79)

1. Rey E, Pons G, Olive G. Vigabatrin clinical pharmacokinetics. Clin Pharmacokinet 1992;23:267-78.
2. Adkins JC, Noble S. Tiagabine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of epilepsy. Drugs 1998;55:437-60.
3. Palmer KJ, McTavish D. Felbamate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in epilepsy. Drugs 1993;45:1041-65.
4. Richens A. Clinical pharmacokinetics of gabapentin. In: Chadwick D, ed. New trends in epilepsy management. London: Royal Society of Medicine Services, 1993:41-6.
5. Rambeck B, Wolf P. Lamotrigine clinical pharmacokinetics. Clin Pharmacokinet 1993;25:433-43.
6. Perucca E, Bialer M. The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine. Clin Pharmacokinet 1996;31:29-46.
7. Langtry HD, Gillis JC, Davis R. Topiramate. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of epilepsy. Drugs 1997;54:752-73.
8. Grant SM, Faulds D. Oxcarbazepine. A review of its pharmacology and therapeutic potential in epilepsy, trigeminal neuralgia and affective disorders. Drugs 1992;43:873-88.
9. Tartara A, Galimberti CA, Manni R, et al. The pharmacokinetics of oxcarbazepine and its active metabolite 10-hydroxy-carbazepine in healthy subjects and in epileptic patients treated with phenobarbitone or valproic acid. Br J Clin Pharmacol 1993;36:306-68.
10. Yuen WC, Peck AW. Lamotrigine pharmacokinetics: oral and intravenous infusion in man. Epilepsia 1988;28:582-6.
11. Goa KL, Sorkin EM. Gabapentin. A review of its pharmacological properties and clinical potential in epilepsy. Drugs 1993;46:409-27.
12. Stewart BH, Kugler AR, Thompson PR, Brockbrader HN. A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of lack of proportionality between increasing dose and drug levels in plasma. Pharm Res 1993;10:276-81.
13. Perucca E. The new generation of antiepileptic drugs: advantages and disadvantages. Br J Clin Pharmacol 1996;42:531-43.
14. Gidal BE, Maly MM, Budde J, Leusmeyer GL, Pitterle ME, Jones JC. Effect of high-protein meal on gahapentin pharmacokinetics. Epilepsy Res 1996;23:71-6.
15. Benetello P, Furlanut M, Fortunato M, et al. Oral gabapentin disposition in patients with epilepsy after a high-protein meal. Epilepsia 1997;38:1140-2.
16. Mengel H, Gustavson LE, Soerensen HJ, et al. Effect of food on the bioavailability of tiagabine HCl [Abstract]. Epilepsia 1991; 32(suppl 3):6.
17. Wilensky AJ, Friel PN, Ojeman LM, Kupferberg HJ, Levy RH. Pharmacokinetics of W-554 (ADD 03055) in epileptic patients. Epilepsia 1993;26:602-5.
18. Welty DF, Schielke GP, Vartanian MG, Taylor CP. Gabapentin anticonvulsant action in rats: disequilibrium with peak drug concentrations in plasma and brain dialysate. Epilepsy Res 1993;16: 175-81.
19. Banfield CR, Zhu GRR, Jen JF, et al. The effect of age on the apparent clearance of felbamate: a retrospective analysis using non-linear mixed effects modeling. Ther Drug Monit 1996;18:19-29.
20. Bartoli A, Guerrini R, Belmonte A, Alessandri MG, Gatti G, Perucca E. The influence of dosage, age and comedication on steady-state plasma lamotrigine concentrations in epileptic children: a prospective study with preliminary assessment of correlations with clinical response. Ther Drug Monit 1997;19:252-60.
21. Gustavson LE, Boellner SW, Granneman GR, et al. A single dose-study to define tiagabine pharmacokinetics in pediatric patients with complex partial seizures. Neurology 1997;48:1032-7.
22. Rey E, Pons G, Richard MO, et al. Pharmacokinetics of the individual enantiomers of vigabatrin (gamma-vinyl-GABA) in epileptic children. Br J Clin Pharmacol 1990;30:253-8.
23. Motte J. Oxcarbazepine in childhood. Presented at the Symposium, Oxcarbazepine - a first-line drug, Sydney, September, 1995.
24. Khurana DS, Riviello J, Helmers S, Holmes G, Anderson J, Mikati M. Efficacy of gabapentin therapy in children with refractory partial seizures. J Pediatr 1996;128(6):829-33.
25. Tomson T, Ohman I, Vitols S. Lamotrigine in pregnancy and lactation: a case report. Epilepsia 1997;38:1039-41.
26. Rambeck B, Kurlemann G, Stodieck SRG, May TW, Jurgens U. Concentrations of lamotrigine in a mother on lamotrigine treatment and her newborn child. Eur J Clin Pharmacol 1997;51:481-4.
27. Bulau P, Paar WD, Von Unruh GE. Pharmacokinetics of oxcarbazepine and 10-hydroxycarbazepine in the newborn child of an oxcarbazepine-treated mother. Eur J Clin Pharmacol 1988;34: 311-3.
28. Tran A, O'Mahoney T, Rey E, Mai J, Mumford JP, Olive G. Vigabatrin: placental transfer in vivo and excretion into breast milk of the enantiomers. Br J Clin Pharmacol 1998;45:409-11.
29. Haegele KD, Huebert ND, Ebel M, Tell GP, Schechter PJ. Pharmacokinetics of vigabatrin: implications of creatinine clearance. Clin Pharmacol Ther 1988;44:558-65.
30. Boyd RA, Bockbrader HN, Turck D, et al. Effect of subject age on the single dose pharmacokinetics of orally administered gabapentin (CI-945) [Abstract]. Pharm Res 1990;7(suppl 9):S215.
31. Posner J, Holdich T, Crome P. Comparison of lamotrigine pharmacokinetics in young and elderly healthy volunteers. J Pharm Med 1991;1:121-8.
32. Van Heiningen PNM, Eve MD, Oosterhuis B, et al. The influence of age on the pharmacokinetics of the antiepileptic agent Oxcarbazepine. Clin Pharmacol Ther 1991;50:410-9.
33. Snel S, Jansen JA, Mengel HB. The pharmacokinetics of tiagabine in healthy elderly volunteers and elderly patients with epilepsy. J Clin Pharmacol 1997;37:1015-20.
34. Andrews CO, Fisher JH. Gabapentin: a new agent for the management of epilepsy. Ann Pharmacother 1994;28:1188-96.
35. Gisclon LG, Riffitts JM, Sica DA, et al. The pharmacokinetics of topiramate in subjects with renal impairment as compared to matched subjects with normal renal function [Abstract]. Pharm Res 1993;10(suppl 10):S397.
36. Rouan MC, Lecaillon JB, Godbillon J, et al. The effect of renal impairment on the pharmacokinetics of oxcarbazepine and its metabolites. Eur J Clin Pharmacol 1994;47:161-7.
37. Cato A III, Gustavson LE, Qian JX, El-Shourbagy T, Kelly EA. Effect of renal impairment on the pharmacokinetics and tolerability of tiagabine. Epilepsia 1998;39:43-7.
38. Schentag JJ, Gengo FM, Wilton JH, et al. Influence of phenobarbital, cimetidine, and renal disease on zonisamide kinetics [Abstract]. Pharm Res 1987;4(suppl):79.
39. Lau AH, Gustavson LE, Sperelakis R, et al. Pharmacokinetics and safety of tiagabine in subjects with various degrees of hepatic function. Epilepsia 1997;38:445-51.
40. DeBony F, Bidault R, Altman C, et al. Lamotrigine pharmacokinetics in subjects with liver cirrhosis [Abstract]. Clin Pharmacol Ther 1997;61:184.
41. Brodie MJ, Richens A, Yuen AW. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet 1995;345:476-9.
42. Kilpatrick ES, Forrest G, Brodie MJ. Concentration-effect and concentration-toxicity relations with lamotrigine: a prospective study. Epilepsia 1996;37:534-8.
43. Fitton A, Goa KL. Lamotrigine. An update of its pharmacology and therapeutic use in epilepsy. Drugs 1995;50:691-713.
44. Goa KL, Ross SR, Chrisp P. Lamotrigine. A review of its pharmacological properties and clinical efficacy in epilepsy. Drugs 1993;46:152-76.
45. Felbamate Study Group in Lennox-Gastaut Syndrome. Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). N Engl J Med 1993;328:29-33.
46. Troupin AS, Montouris G, Hussein G. Felbamate: therapeutic range and other kinetic information. J Epilepsy 1997;10:26-31.
47. Mawer GE, Pleuvry BJ. Interactions involving new antiepileptic drugs. Pharmacol Ther 1995;68:209-31.
48. Rambeck B, Specht U, Wolf P. Pharmacokinetic interactions of the new antiepileptic drugs. Clin Pharmacokinet 1996;31:309-24.
49. Colucci R, Glue P, Holt B, et al. Effect of felbamate on the pharmacokinetics of lamotrigine. J Clin Pharmacol 1996;36:634-8.
50. Reidenberg P, Glue P, Banfield C, et al. Pharmacokinetic interaction studies between felbamate and vigabatrin. Br J Clin Pharmacol 1995;40:157-60.
51. Hulsman JARJ, Rentmeester TW, Banfield CR, et al. Effects of felbamate on the pharmacokinetics of the monohydroxy and dihydroxy metabolites of oxcarbazepine. Clin Pharmacol Ther 1995; 58:383-9.
52. Saano V, Glue P, Banfield CR, et al. Effects of felbamate on the pharmacokinetics of a low-dose combination oral contraceptive. Clin Pharmacol Ther 1995;58:523-31.
53. Eldon MA, Underwood BA, Randinitis EJ, Posvar EL, Sedman AJ. Lack of an effect of gabapentin on the pharmacokinetics of a norethindrone acetate (ethinylestradiol) containing oral contraceptive [Abstract]. Neurology 1993;43:A307.
54. Holdich T, Whiteman P, Orme M, Back D, Ward S. Effect of lamotrigine on the pharmacology of the combined oral contraceptive pill [Abstract]. Epilepsia 1991;32(suppl 1):96.
55. Besag FMC, Berry DJ, Pool F, Newbery JE, Subel B. Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interaction? Epilepsia 1998;39:183-7.
56. May TW, Rambeck B. Influence of oxcarbazepine and methsuximide on lamotrigine concentrations [Abstract]. Epilepsia 1998;39 (suppl 2):25.
57. Besag FMC, Berry DJ, Pool F. Methsuximide lowers lamotrigine blood levels: a pharmacokinetic antiepileptic drug interaction [Abstract]. Epilepsia 1998;39(suppl 2):25.
58. Kaufman KR, Gerner R. Lamotrigine toxicity secondary to sertraline. Epilepsia 1997;38(suppl 8):100-1.
59. Depot M, Powell JR, Messenheimer JA, Cloutier G, Dalton MJ. Kinetic effects of multiple oral doses of acetaminophen on a single oral dose of lamotrigine. Clin Pharmacol Ther 1990;48:346-55.
60. Brodie MJ, Yuen AWC, and the 105 Study Group. Lamotrigine substitution study: evidence for synergism with sodium valproate. Epilepsy Res 1997;26:423-32.
61. Pisani F, Perucca E, Richens A, Di Perri R. Interaction of lamotrigine with sodium valproate. Lancet 1993;341:1224.
62. Pisani F, Oteri G, Russo M, et al. Effects of lamotrigine-valproate comedication on seizure frequency and upper limb tremor: a pharmacodynamic interaction? [Abstract]. Epilepsia 1995;36(suppl 3): S264.
63. Robinson MK, Black AB, Schapel GS, Lam E. Combined gammavinyl GABA (vigabatrin) and lamotrigine therapy in management of refractory epilepsy [Abstract]. Epilepsia 1993;34(suppl 2): 109.
64. Panayiotopoulos CP, Ferrie CD, Knott C, Robinson RO. Interaction of lamotrigine with sodium valproate. Lancet 1993;341:445.
65. Pisani F, Oteri G, Russo MF, et al. The efficacy of valproatelamotrigine comedication in refractory complex partial seizures: evidence for a pharmacodynamic interaction. Epilepsia 1999; 40:1141-6.
66. Reutens DC, Duncan JS, Patsalos PN. Disabling tremor after lamotrigine with sodium valproate. Lancet 1993;342:185-6.
67. Houtkooper MA, Lammertsma A, Meijer JWA, et al. Oxcarbazepine (GP 47,680): a possible alternative to carbamazepine? Epilepsia 1987;28:693-8.
68. Baruzzi A, Albani F, Riva R. Oxcarbazepine: pharmacokinetic interactions and their clinical relevance. Epilepsia 1994;35(suppl 3):S14-9.
69. Klosterkov Jensen P, Saano V, Haring P, Svenstrup B, Menge GP. Possible interaction between oxcarbazepine and an oral contraceptive. Epilepsia 1992;33:1149-52.
70. Fattore C, Cipolla G, Gatti G, et al. Induction of ethynylestradiol and levonorgestel metabolism by oxcarbazepine in healthy women. Epilepsia 1999;40:783-7.
71. Mengel HB, Houston A, Back DJ. An evaluation of the risk of interaction between tiagabine and oral contraceptives in female volunteers. J Pharm Med 1994;4:141-50.
72. Adkins JC, Noble S. Tiagabine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of epilepsy. Drugs 1998;55:437-60.
73. Rosenfeld WE, Doose DR, Walker SA, Nayak RK. Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy. Epilepsia 1997;38:317-23.
74. Sachdeo RC, Sachdeo SK, Walker SA, Kramer LD, Nayak RK, Doose DR. Steady-state pharmacokinetics of topiramate and carbamazepine in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia 1996;37:774-80.
75. Rosenfeld WE, Liao S, Kramer LD, et al. Comparison of the steady-state pharmacokinetics of topiramate and valproate in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia 1997;38:324-33.
76. Rimmer EM, Richens A. Interaction between vigabatrin and phenytoin. Br J Clin Pharmacol 1989;27:27S-33S.
77. Bartoli A, Cipolla G, Barzaghi N, et al. A double-blind, placebo-controlled study on the effect of vigabatrin on in vivo parameters of hepatic microsomal enzyme induction and on the kinetics of steroid oral contraceptives in healthy female volunteers. Epilepsia 1997;38:702-7.
78. Gatti G, Bartoli A, Marchiselli R, et al. Vigabatrin-induced decrease in serum phenytoin concentration does not involve a change in phenytoin bioavailability. Br J Clin Pharmacol 1993;36:603-6.
79. Szylleyko OJ, Hoke JF, Eller MG, Weir S, Zobrist RH, Sussman NM. A definitive study evaluating the pharmacokinetics of vigabatrin in patients with epilepsy. Epilepsia 1993;34(suppl 6):41-2.